1.79

2.72% -0.05

Cardiol Therapeutics Inc (CRDL)

Overview News Price History Option Chain Why CRDL Down? Discussions Forecast

Cardiol Therapeutics Inc stock is currently priced at $1.79, with a 24-hour trading volume of 104.74K. It has seen a -2.72% decreased in the last 24 hours and a -1.65% declined in the past month. The chart indicates a potential bullish trend, as the stock is below the $1.79 pivot point. If it approaches the $1.74 support level, significant changes may occur.

Previous Close:

$1.84

Open:

$1.81

24h Volume:

104.74K

Market Cap:

$122.20M

Revenue:

Net Income/Loss:

$-20.75M

P/E Ratio:

-5.0983

EPS:

-0.3511

Net Cash Flow:

$-23.71M

1W Performance:

+1.13%

1M Performance:

-1.65%

6M Performance:

+123.67%

1Y Performance:

+203.39%

1D Range:

$1.74

$1.84

52W Range:

$0.55

$2.17

Cardiol Therapeutics Inc Stock (CRDL) Company Profile

Name

Cardiol Therapeutics Inc

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

Address

2265 Upper Middle Road East, Suite 602, Oakville

Employee

Twitter

Next Earnings Date

2024-05-17

Latest SEC Filings

CRDL's Discussions on Twitter

Cardiol Therapeutics Inc Stock (CRDL) Financials Data

Cardiol Therapeutics Inc (CRDL) Net Income 2024

CRDL net income (TTM) was -$20.75 million for the quarter ending September 30, 2023, a +10.63% increase year-over-year.

Cardiol Therapeutics Inc (CRDL) Cash Flow 2024

CRDL recorded a free cash flow (TTM) of -$23.71 million for the quarter ending September 30, 2023, a -63.29% decrease year-over-year.

Cardiol Therapeutics Inc (CRDL) Earnings per Share 2024

CRDL earnings per share (TTM) was -$0.3186 for the quarter ending September 30, 2023, a +9.44% growth year-over-year.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.